The Prescrire Drug Awards focus on products evaluated during the previous year in the New Products section of Prescrire's French edition (issues 303 to 314 in 2009).
In 2009, as in 2008, no drugs were awarded Prescrire's "Pilule d'Or" ("Golden Pill") or added to the Honours List.
PILULE D'OR / GOLDEN PILL |
The “Golden Pill” award is granted to drugs that provide a major therapeutic advance in a field in which no effective treatment was previously available. |
NOT ATTRIBUTED IN 2009 |
HONOURS LIST
|
The drugs included on the Honours List provide a clear advantage for some patients in comparison to existing therapeutic options, albeit with certain limitations. |
NO INCLUSIONS IN 2009 |
NOTEWORTHY |
The following drugs (in alphabetical order of their international nonproprietary names (INN), the drug’s real name) made a modest contribution to patient care: |
caspofungin |
CANCIDAS° MSD-Chibret |
Invasive aspergillosis in children in whom injectable amphotericin B and/or itraconazole is ineffective or poorly tolerated (Prescrire Int 102) |
thalidomide |
THALIDOMIDE CELGENE° Celgene |
First-line treatment of multiple myeloma in selected patients over 65 years of age, in combination with melphalan and prednisone (Prescrire Int 100) |
©Prescrire April 2010
Source: Prescrire Int 2010; 19 (106): 86. |